Literature DB >> 18799068

Proteinase 3, protease-activated receptor-2 and interleukin-32: linking innate and autoimmunity in Wegener's granulomatosis.

E Csernok1, J U Holle, W L Gross.   

Abstract

Proteinase 3 (PR3) is a multifunctional neutrophil-derived serine protease influencing cell cycle, differentiation, and cell death. This molecule is the main target antigen of autoantibodies in Wegener's granulomatosis (WG) known as antineutrophil cytoplasmic antibodies (PR3-ANCA). WG usually starts as granulomatous inflammation of the upper respiratory tract (localized phase) and progress to systemic disease with PR3-ANCA-associated vasculitis (generalized phase). PR3-ANCA is thought to play a critical role in the pathogenesis of vascular damage in WG. In contrast, it is not clear how the granulomatous inflammation, the hallmark of WG, is driven, and what is the relationship between granuloma and autoimmunity. Recent findings provide evidence that PR3 might function as endogenous "danger/alarm" signal that communicates the presence of tissue injury to dendritic cells (DC) via protease-activated receptor-2 (PAR-2), triggers their maturation and instructs DC to induce Th1-type cell responses in WG. Furthermore, PR3 has the capacity to bind and activate IL-32, a recently discovered proinflammatory cytokine that has emerged as an important player in innate and adaptive immune response.Collectively, these results delineate new pathogenic pathways at the molecular level and provide insights into the mechanisms by which PR3 may contribute to the early pathogenesis of WG supporting the pivotal role of the interaction of Wegener's autoantigen with the "gateway" receptor PAR-2 in mediating both innate and adaptive immune response in WG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799068

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  10 in total

1.  B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer.

Authors:  Lucius Bader; Wenche Koldingsnes; Johannes Nossent
Journal:  Clin Rheumatol       Date:  2010-06-28       Impact factor: 2.980

2.  Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Authors:  Tian-Hui Yang; Lisa S St John; Haven R Garber; Celine Kerros; Kathryn E Ruisaard; Karen Clise-Dwyer; Gheath Alatrash; Qing Ma; Jeffrey J Molldrem
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

3.  Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma.

Authors:  Hyun-Jung Lee; Zhe Long Liang; Song Mei Huang; Jae-Sung Lim; DO-Young Yoon; Hyo-Jin Lee; Jin Man Kim
Journal:  Oncol Lett       Date:  2011-12-02       Impact factor: 2.967

4.  Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32.

Authors:  Y Qu; J L Taylor; A Bose; W J Storkus
Journal:  Cancer Gene Ther       Date:  2011-07-15       Impact factor: 5.987

5.  IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis.

Authors:  Masanori Nakayama; Yasuo Niki; Toshiki Kawasaki; Yuki Takeda; Hiroyasu Ikegami; Yoshiaki Toyama; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2013-10-16       Impact factor: 4.379

6.  Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.

Authors:  Guillaume Mabilleau; Afsie Sabokbar
Journal:  PLoS One       Date:  2009-01-12       Impact factor: 3.240

Review 7.  T cell-macrophage interactions and granuloma formation in vasculitis.

Authors:  Marc Hilhorst; Tsuyoshi Shirai; Gerald Berry; Jörg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2014-09-12       Impact factor: 7.561

8.  Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells.

Authors:  Xuanru Lin; Li Yang; Gang Wang; Fuming Zi; Haimeng Yan; Xing Guo; Jing Chen; Qingxiao Chen; Xi Huang; Yi Li; Enfan Zhang; Wenjun Wu; Yang Yang; Donghua He; Jingsong He; Zhen Cai
Journal:  Oncotarget       Date:  2017-10-07

9.  Longitudinal expression profiling of CD4+ and CD8+ cells in patients with active to quiescent giant cell arteritis.

Authors:  Elisabeth De Smit; Samuel W Lukowski; Lisa Anderson; Anne Senabouth; Kaisar Dauyey; Sharon Song; Bruce Wyse; Lawrie Wheeler; Christine Y Chen; Khoa Cao; Amy Wong Ten Yuen; Neil Shuey; Linda Clarke; Isabel Lopez Sanchez; Sandy S C Hung; Alice Pébay; David A Mackey; Matthew A Brown; Alex W Hewitt; Joseph E Powell
Journal:  BMC Med Genomics       Date:  2018-07-23       Impact factor: 3.063

Review 10.  Immunopathogenesis of ANCA-Associated Vasculitis.

Authors:  Andreas Kronbichler; Keum Hwa Lee; Sara Denicolò; Daeun Choi; Hyojeong Lee; Donghyun Ahn; Kang Hyun Kim; Ji Han Lee; HyungTae Kim; Minha Hwang; Sun Wook Jung; Changjun Lee; Hojune Lee; Haejune Sung; Dongkyu Lee; Jaehyuk Hwang; Sohee Kim; Injae Hwang; Do Young Kim; Hyung Jun Kim; Geonjae Cho; Yunryoung Cho; Dongil Kim; Minje Choi; Junhye Park; Junseong Park; Kalthoum Tizaoui; Han Li; Lee Smith; Ai Koyanagi; Louis Jacob; Philipp Gauckler; Jae Il Shin
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.